- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma
- Ajax Therapeutics Presents Overview of Ph 1 Clinical Trial Evaluating AJ1 11095 for the Treatment of Myelofibrosis
- Blenrep shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
- DARZALEX FASPRO (daratumumab & hyaluronidase-fihj)-based regimens demonstrate improved rates of MRD negativity and PFS in patients with newly diagnosed multiple myeloma
- DARZALEX FASPRO® shows 51% reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
- Encouraging New Results from Ph 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with R/R NHL announced
- Five-year results confirm Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
- Fixed-duration Calquence + venetoclax demonstrated superior PFS vs. SoC in 1L CLL, with 77% of patients progression free at three years in AMPLIFY Ph 3 trial
- Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with R/R NHL
- Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
- Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and CRRs in Clinical Trial of Patients With R/R CLL in Preliminary Analysis
- Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With R/R FL
- Kite Presents New Data Underscoring Curative Potential of Yescarta® in R/R Large B-cell Lymphoma
- Longer-term data for Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
- Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with R/R LBCL
- Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials
- TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
- Two Data Analyses Show Epcoritamab Induces Durable Complete Responses As Monotherapy and Combination Treatment in Patients With DLBCL
- Wugen to Present Clinical Data Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
- Zilovertamab Vedotin + R-CHP Demonstrates CRR of 100% at 1.75 mg/kg Dose in Ph 2 Trial of Previously Untreated DLBCL Patients
Menu
